Physician profile
Jay Bradley
NPI 1912042763
$290,387.07
in general payments reported to CMS, 2019-2025
35 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,080 · 2020: $39K · 2021: $20K · 2022: $60K · 2023: $51K · 2024: $57K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $162K · Food and Beverage: $4,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $162,231.40 |
| Food and Beverage | $4,171.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $162,231.40 | 2023-2025 | |
| Csl Behring | $114,703.20 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $3,125.33 | 2019-2024 | Veritas Vision System |
| Allergan, INC. | $2,637.59 | 2019-2022 | |
| Lumenis Be INC | $1,380.98 | 2024 | M22 |
| Abbvie INC. | $1,170.98 | 2022-2025 | Botox, Lumigan, Alphagan P |
| Ocular Therapeutix, INC. | $845.01 | 2019-2025 | Dextenza |
| Ivantis, INC | $712.62 | 2019-2021 | |
| Alcon Vision LLC | $703.13 | 2019-2025 | Hydrus Microstent, Eysuvis |
| Glaukos Corporation | $316.96 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $314.09 | 2019 | |
| Oyster Point Pharma, INC. | $253.27 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $223.45 | 2019-2021 | |
| Shire North American Group INC | $213.25 | 2019 | |
| Sight Sciences, INC. | $191.60 | 2019-2023 | Omni Surgical System |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $175.62 | 2020-2024 | |
| Bausch & Lomb Americas INC. | $152.39 | 2022-2024 | Vyzulta, Xiidra, Miebo |
| Genentech USA, INC. | $126.74 | 2023 | Vabysmo |
| Omeros Corporation | $106.38 | 2019 | |
| Optos, INC. | $105.69 | 2019-2021 | |
| Exactech, INC. | $102.43 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $97.59 | 2024-2025 | Eylea Hd, Eylea |
| Horizon Therapeutics Plc | $89.47 | 2023 | Tepezza |
| Dompe US, INC. | $66.61 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $58.89 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $52.75 | 2022-2023 | |
| Lensar, INC. | $41.63 | 2019-2025 | Lensar Laser System |
| Alimera Sciences, INC. | $41.13 | 2024 | Yutiq, Iluvien |
| Biotissue Holdings INC. | $40.69 | 2019 | |
| Ani Pharmaceuticals, INC. | $28.30 | 2025 | Yutiq, Purified Cortrophin Gel |
| Amgen INC. | $17.71 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $17.50 | 2024 | Xdemvy |
| Galderma Laboratories, L.P. | $17.18 | 2019 | |
| Harrow Eye, LLC | $17.06 | 2025 | |
| Topcon Healthcare, INC. | $8.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.